Repligen Corporation (RGEN) AI Stock Analysis
RGEN AI stock analysis summary
AI ResearchRepligen Corporation (RGEN) produces critical bioprocessing systems and consumables used in biological drug manufacturing. The business rebounded in FY2025 with revenue rising 16.4% to $738.3M and net income reaching $48.9M. The company maintains net cash of $119.5M, but trades at an elevated trailing price-to-earnings multiple of 240.3x.
- Market cap
- $11.14B
- Revenue (TTM)
- $785.1M
- P/E
- 240.3x fwd 67.1x
- 1Y return
- 13.5% S&P 500 16.8%
- Avg. target
- $197.95 12.8% vs last close
Bull case
- Revenue returned to double-digit growth in FY2025, climbing 16.4% to $738.3M alongside $93.9M in free cash flow.
- The balance sheet remains solid with $119.5M in net cash and a current ratio of 9.05 as of June 30, 2026.
- Wall Street expectations call for 29.3% EPS growth and 29.7% revenue growth in the next fiscal year.
Bear case
- Valuation multiples are steep, with a trailing P/E of 240.3x and an EV/EBITDA of 53.6x versus the US-listed Healthcare peer medians of 24.6x and 12.0x.
- Quarterly net earnings fell 65.9% year-over-year in the quarter ended June 30, 2026.
- Gross margin of 47.1% in FY2025 remains significantly below the 58.3% reported in FY2021.
What Repligen does
Repligen Corporation develops and commercializes advanced bioprocessing technologies used globally for biologic drug manufacturing. Its product line features Protein A ligands and cell culture growth factors to support biologic production. Core offerings include chromatography tools such as OPUS pre-packed columns, ELISA test kits, and CaptivA resins. The company provides filtration systems such as XCell Alternating Tangential Flow systems, TangenX flat sheet cassettes, and KrosFlo filtration systems. It also markets Spectra/Por dialysis products and process analytics solutions, including slope spectroscopy systems.
Growth and profitability
Repligen achieved a five-year revenue CAGR of 15.0% from FY2020 to FY2025. After post-pandemic contractions in FY2023 and FY2024, FY2025 revenue rose 16.4% to $738.3M, returning to profitability with net income of $48.9M and an operating margin of 8.1%. Gross margin in FY2025 was 47.1%, down from 58.3% in FY2021. For the trailing twelve months, revenue reached $785.1M with an operating margin of 9.3% and net margin of 5.3%. In the quarter ended June 30, 2026, quarterly revenue increased 11.9% year-over-year, while quarterly earnings dropped 65.9%.
Balance sheet and cash flow
As of June 30, 2026, Repligen reported $810.4M in cash and short-term investments against $690.9M in total debt, yielding a net cash balance of $119.5M. Liquidity is strong with a current ratio of 9.05 and a debt-to-equity ratio of 0.33. Operating cash flow totaled $117.4M in FY2025, generating $93.9M in free cash flow after $23.5M in capital expenditures. Share count declined 1.8% over the trailing five-year period.
Valuation and performance
Repligen carries a market capitalization of $11.14B and an enterprise value of $10.29B. The stock trades at a trailing P/E of 240.3x and a forward P/E of 67.1x, well above the US-listed Healthcare median of 24.6x trailing and 17.3x forward. Its EV/EBITDA stands at 53.6x compared to the peer median of 12.0x, and its price-to-sales multiple is 14.2x against 4.1x for peers. Over the trailing 12 months, RGEN gained 13.5%, trailing the S&P 500 return of 16.8%, while its five-year return of -34.3% lags the benchmark's 83.0% gain.
What analysts expect
Wall Street sentiment is positive, with 15 Strong Buy, 3 Buy, and 4 Hold ratings among covering analysts. The mean price target of $197.95 implies 12.8% upside from the October 16, 2026 closing price of $175.42. For the fiscal year ending December 31, 2026, consensus estimates project EPS of $2.06 on revenue of $833.3M. For the following fiscal year, six analysts project revenue of $1.08B and EPS of $2.67. Repligen has beaten EPS estimates in each of the last 4 quarters, with its next earnings scheduled for October 27, 2026.
Key risks and what to watch
- Short interest represents 13.5% of the float, reflecting meaningful bearish market positioning.
- Gross margin compressed from 58.3% in FY2021 to 47.1% in FY2025, which may pressure trailing twelve-month profit margins of 5.3%.
- Quarterly earnings volatility remains high, demonstrated by a 65.9% earnings decline in the quarter ended June 30, 2026.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this RGEN AI stock analysis
This page is an AI-written research summary of Repligen Corporation (RGEN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: RGEN income statement, RGEN balance sheet, RGEN key metrics, RGEN analyst forecast, RGEN chart. See the RGEN stock overview for the latest quote and news.
RGEN AI stock analysis FAQ
Does Repligen pay a dividend?
Repligen does not pay a dividend, instead reinvesting its capital into internal development and capital expenditures, which were $23.5M in FY2025.
What is Repligen's net cash position?
As of June 30, 2026, Repligen had $810.4M in cash and short-term investments and $690.9M in total debt, resulting in net cash of $119.5M.
How did Repligen perform relative to the S&P 500?
Over the past year, Repligen returned 13.5% compared to 16.8% for the S&P 500, while over five years it fell 34.3% compared to an 83.0% gain for the benchmark index.
When is Repligen's next earnings report?
Repligen is scheduled to release its next earnings report on October 27, 2026.